Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

M6ATCELL

Financiado

Exploiting fundamental insights of m6A methylation on CD8 T cell differentiation...

Exploiting fundamental insights of m6A methylation on CD8 T cell differentiation and function to boost medicinal T cell products Adoptive T cell therapies have revolutionised cancer treatment in some haematological tumours. Despite astounding advances, patients often relapse because the transferred T cells have low persistence and they lose their effector f... ver más

30/09/2025

Stichting Sanquin...

235K€

Presupuesto del proyecto: 235K€

Líder del proyecto

Stichting Sanquin Bloedvoorziening No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-27

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Stichting Sanquin Bloedvoorz...

234.53K€ | Lider

EMA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2011-27658 LA ABERRACION DE LA IMPROMTA GENOMICA EN CANCER, UN EVENTO D... 128K€ Cerrado

EUR2019-103835 DIFERENCIACION DE LINFOCITOS B; DESCIFRANDO LOS MECANISMOS D... Cerrado

EpigenomeProgramming An experimental and bioinformatic toolbox for functional epi... 1M€ Cerrado

SAF2009-08663 CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS 114K€ Cerrado

PID2020-116291RB-I00 CARACTERIZACION DE MECANISMOS MOLECULARES IMPLICADOS EN DESA... 284K€ Cerrado

PID2021-123635NB-I00 COMPRENDER EL PAPEL DE LA METILACION DEL ADN EN PROMOTORES C... 182K€ Cerrado

Duración del proyecto: 30 meses Fecha Inicio: 2023-03-27
Fecha Fin: 2025-09-30

Líder del proyecto

Stichting Sanquin Bloedvoorziening No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 235K€

Descripción del proyecto Adoptive T cell therapies have revolutionised cancer treatment in some haematological tumours. Despite astounding advances, patients often relapse because the transferred T cells have low persistence and they lose their effector function against cancer cells. The prime challenge for improving T cell therapies is to decipher the mechanisms that define T cell effector function and memory formation. The MA6TCELL project aims to disentangle this problem by defining how m6A methylation on mRNA regulates human CD8 T cell differentiation and function. m6A is the most abundant mRNA methylation and determines gene expression by regulating mRNA metabolism, altering as such cell function. Using the miCLIP assay, I previously mapped genome-wide the m6A sites on the mRNAs of human CD8 T cells (unpublished data I will provide the host with). This map revealed that m6A occurs not only at the known DRACH sequences, but also at AU-rich sequences (AREs). Intriguingly, the host has uncovered that AREs are critical regulators of cytokine production in memory CD8 T cells (host expertise). My pilot experiments revealed that chemical inhibition of a m6A demethylase in CD8 T cells decreased cytokine production, further supporting my hypothesis that m6A methylation controls CD8 T cell differentiation and function. To test this hypothesis the M6ATCELL project will: 1) define the regulatory mechanisms of m6A methylation in human CD8 T cell differentiation and effector function and 2) test whether m6A enzyme inhibitors improve the potency of CD8 T cell therapies using chimeric antigen receptor (CAR) T cells. Our findings will yield fundamental insights in T cell biology, which can be relevant for multiple adoptive T cell therapies. My long-term aim is to transfer my scientific findings from bench-to-bedside. Thus, I also secured a placement at the European Medicines Agency and if this proposal is granted, I will be trained on the regulatory guidelines of medicinal T cell products.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores